Stock Financial Ratios and Split History
ADRO / Aduro Biotech, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.
|Market Cap ($M)||745.26|
|Enterprise Value ($M)||591.70|
|Book Value ($M)||237.47|
|Book Value / Share||2.93|
|Price / Book||3.14|
|NCAV / Share||1.84|
|Price / NCAV||4.99|
|Income Statement (mra) ($M)|
|Balance Sheet (mrq) ($M)|
|Cash & Equivalents||0.00|
|Cash / Share||0.00|
|Common Stock Shares Outstanding||77,736,201|
|Common Shares Outstanding||81,006,486|
|Preferred Stock Shares Outstanding||0|
|Altman Z Score||N/A|
|Beneish M Score||N/A|
|Cash Conversion Cycle||N/A|
|Management Effectiveness (mra)|
|Return on Invested Capital (ROIC)||-0.39|
|Return on Assets (ROA)||-0.21|
|Return on Equity (ROE)||-0.40|
|Identifiers and Descriptors|
|Central Index Key (CIK)||1435049|
|SIC 2834 - Pharmaceutical Preparations|
Stock splits are used by Aduro Biotech, Inc. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.
Peers - Pharmaceutical Preparations (2834)
ENDV / Endonovo Therapeutics, Inc.
AXIM / Axim Biotechnologies, Inc.
PRTT / Protect Pharmaceutical Corp
NNAB / NanoAntibiotics, Inc.
Related News Stories
Aduro Biotech, Inc. (ADRO - Free Report) reported fourth-quarter 2017 loss of 34 cents per share, narrower than both the Zacks Consensus Estimate of a loss of 36 cents and the year-ago loss of 44 cents. (29-2)
February was a crazy month for investors; consequently, the landscape of best-performing exchange-traded funds expanded from primarily biotech and emerging-market ETFs in January to several other spaces for this edition of the best ETFs of the month. (332-2)
Armo BioSciences is a Silicon Valley-based immune-oncology company that recently launched its $128M IPO on Nasdaq. (88-0)